지놈앤컴퍼니
Financials
Valuation Metrics
지놈앤컴퍼니's Market Cap is ₩1878B. At end of 2025 it was ₩3698B. Ranked #830 of 2,405 in KR market (top 35%), #375 of 1,627 on KOSDAQ (top 23%), #91 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 39%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 187.85B KRW | KR#830/2,405 Sec#91/231 |
| Revenue | 24.46B KRW | KR#2,090/2,405 Sec#149/231 |
| Net Income | -43.18B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 122.98B KRW | KR#1,636/2,405 Sec#130/231 |
| Net Assets | 81.29B KRW | KR#1,576/2,405 Sec#127/231 |
| Employees | 102 | KR#1,620/2,405 Sec#128/231 |
| Value | ||
| P/B | 2.31x | KR#2,047/2,405 Sec#158/231 |
| P/S | 7.68x | KR#2,244/2,405 Sec#160/231 |
| FCF Yield | -9.94% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -53.12% | KR#2,269/2,405 Sec#198/231 |
| ROA | -35.11% | KR#2,319/2,405 Sec#205/231 |
| Op. Margin | -119.33% | KR#2,300/2,405 Sec#179/231 |
| Revenue Growth | 1.84% | KR#1,394/2,405 Sec#137/231 |
| Financial Health | ||
| Debt Ratio | 51.28% | KR#972/2,405 Sec#113/231 |
| Total Debt | 21.42B KRW | KR#1,350/2,405 Sec#108/231 |
| FCF | -18.67B KRW | KR#1,869/2,405 Sec#178/231 |
| Cash | 49.91B KRW | KR#738/2,405 Sec#42/231 |
| Current Ratio | 2.31x | KR#745/2,405 Sec#89/231 |
| Performance | ||
| 1Y Return | 9.22% | KR#549/2,405 Sec#27/231 |
| 1M Return | -36.45% | KR#2,321/2,405 Sec#225/231 |
| From 52W High | -65.67% | KR#1,919/2,405 Sec#165/231 |
| 1Y MDD | -70.01% | KR#1,957/2,405 Sec#166/231 |
| Trading | ||
| Volume | 144,714 shares | KR#491/2,405 Sec#53/231 |
| Trading Value | 506.4M KRW | KR#793/2,405 Sec#84/231 |
| Foreign Own. | 3.74% | KR#1,103/2,405 Sec#100/231 |
| Per Share | ||
| EPS | -803 KRW | KR—/2,405 Sec—/231 |
| BPS | 1,513 KRW | KR#2,193/2,405 Sec#190/231 |
Company Info
Established in 2015, this global new drug development specialized company went public on KOSDAQ in 2020 and subsequently acquired the management rights of List Labs, a US microbiome CDMO company. Leveraging its Genocle new drug development platform, it researches and develops anticancer drugs and microbiome medicines. The company also operates CDMO, microbiome cosmetics, and health functional food businesses, aiming for integrated pharmaceutical company growth through clinical data-based new drug development and technology transfer commercialization.